The metabolic score of insulin resistance is positively correlated with bone mineral density in postmenopausal patients with type 2 diabetes mellitus. 2023

Peng Gu, and Bin Pu, and Qiao Xin, and Dan Yue, and LieLiang Luo, and JiaSheng Tao, and HaiShan Li, and Ming Chen, and MingHua Hu, and XiaoRong Hu, and XiaoHui Zheng, and ZhanPeng Zeng
Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

The prevalence of type 2 diabetes mellitus (T2DM) complicated with osteoporosis (OP) is increasing yearly. Early prevention, detection and treatment of OP are important in postmenopausal patients with T2DM. This study aimed to explore the correlation between insulin resistance and bone mineral density (BMD), and OP in postmenopausal patients with T2DM. In this study, postmenopausal patients with T2DM who visited our hospital from January 2021 to March 2022 were divided into the OP group (n = 91) and non-OP group (n = 119) according to whether they were complicated with OP or not. The general data of patients, BMD, blood routine, glucose metabolism, lipid metabolism, liver and kidney function indexes were collected, and the homeostatic model assessment for IR (HOMA-IR), the triglyceride-glucose (TyG) index and the metabolic score for IR (METS-IR) were calculated. A weighted multivariate linear regression model assessed the correlation between insulin resistance (IR) related indexes and lumbar spine, femoral neck, and hip BMD. A weighted logistic regression model assessed the odds ratios (ORs) and 95% confidence intervals (95% CIs) for the association between the IR-related indexes and OP risk. The nonlinear relationship was also evaluated by smooth curve fitting (SCF) and a weighted generalized additive model (GAM). Moreover, the Receiver-operating characteristics (ROC) curve was used to analyze the predictive efficiency of METS-IR in postmenopausal patients with T2DM with OP. HOMA-IR, TyG, and METS-IR in the OP group were lower than those in the non-OP group (all P < 0.05). Weighted multiple linear regression after adjusting covariates showed that METS-IR was positively correlated with the lumbar spine, femoral neck, and hip BMD (βMETS-IR = 0.006,0.005,0.005, all P < 0.001). The results of weighted Logistic regression and GAM showed that when METS-IR < 44.5, each unit of increased METS-IR value was associated with a decreased OP risk of 12% (P = 0.002). When METS-IR ≥ 44.5, there was no significant correlation between METS-IR and the risk of OP (OR = 1.00, P = 0.934). Similar trends were not observed in HOMA-IR and TyG. The ROC suggested helpful discriminative power of the METS-IR index for T2DM. We confirmed that METS-IR, as a novel alternative marker of IR, had a positive association with BMD in postmenopausal patients with T2DM, and METS-IR was a protective factor for OP in a specific range.

UI MeSH Term Description Entries
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015519 Bone Density The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS. Bone Mineral Content,Bone Mineral Density,Bone Densities,Bone Mineral Contents,Bone Mineral Densities,Density, Bone,Density, Bone Mineral
D017698 Postmenopause The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life. Post-Menopause,Post-menopausal Period,Postmenopausal Period,Period, Post-menopausal,Period, Postmenopausal,Post Menopause,Post menopausal Period,Post-Menopauses

Related Publications

Peng Gu, and Bin Pu, and Qiao Xin, and Dan Yue, and LieLiang Luo, and JiaSheng Tao, and HaiShan Li, and Ming Chen, and MingHua Hu, and XiaoRong Hu, and XiaoHui Zheng, and ZhanPeng Zeng
January 2008, Annals of Saudi medicine,
Peng Gu, and Bin Pu, and Qiao Xin, and Dan Yue, and LieLiang Luo, and JiaSheng Tao, and HaiShan Li, and Ming Chen, and MingHua Hu, and XiaoRong Hu, and XiaoHui Zheng, and ZhanPeng Zeng
October 2019, Menopause (New York, N.Y.),
Peng Gu, and Bin Pu, and Qiao Xin, and Dan Yue, and LieLiang Luo, and JiaSheng Tao, and HaiShan Li, and Ming Chen, and MingHua Hu, and XiaoRong Hu, and XiaoHui Zheng, and ZhanPeng Zeng
March 2017, Acta clinica Croatica,
Peng Gu, and Bin Pu, and Qiao Xin, and Dan Yue, and LieLiang Luo, and JiaSheng Tao, and HaiShan Li, and Ming Chen, and MingHua Hu, and XiaoRong Hu, and XiaoHui Zheng, and ZhanPeng Zeng
January 2012, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry,
Peng Gu, and Bin Pu, and Qiao Xin, and Dan Yue, and LieLiang Luo, and JiaSheng Tao, and HaiShan Li, and Ming Chen, and MingHua Hu, and XiaoRong Hu, and XiaoHui Zheng, and ZhanPeng Zeng
June 2007, Acta diabetologica,
Peng Gu, and Bin Pu, and Qiao Xin, and Dan Yue, and LieLiang Luo, and JiaSheng Tao, and HaiShan Li, and Ming Chen, and MingHua Hu, and XiaoRong Hu, and XiaoHui Zheng, and ZhanPeng Zeng
January 2015, Journal of physical therapy science,
Peng Gu, and Bin Pu, and Qiao Xin, and Dan Yue, and LieLiang Luo, and JiaSheng Tao, and HaiShan Li, and Ming Chen, and MingHua Hu, and XiaoRong Hu, and XiaoHui Zheng, and ZhanPeng Zeng
January 2021, Diabetes, metabolic syndrome and obesity : targets and therapy,
Peng Gu, and Bin Pu, and Qiao Xin, and Dan Yue, and LieLiang Luo, and JiaSheng Tao, and HaiShan Li, and Ming Chen, and MingHua Hu, and XiaoRong Hu, and XiaoHui Zheng, and ZhanPeng Zeng
January 2022, Disease markers,
Peng Gu, and Bin Pu, and Qiao Xin, and Dan Yue, and LieLiang Luo, and JiaSheng Tao, and HaiShan Li, and Ming Chen, and MingHua Hu, and XiaoRong Hu, and XiaoHui Zheng, and ZhanPeng Zeng
January 2022, Frontiers in endocrinology,
Peng Gu, and Bin Pu, and Qiao Xin, and Dan Yue, and LieLiang Luo, and JiaSheng Tao, and HaiShan Li, and Ming Chen, and MingHua Hu, and XiaoRong Hu, and XiaoHui Zheng, and ZhanPeng Zeng
September 2023, Medicine,
Copied contents to your clipboard!